|
|
 |
|
Viewing report
|
|
|
|
Prescription Drug Counterfeiting
Drug and Market Development Publishing, April 2007, Pages: 79
This Prescription Drug Counterfeiting report includes recent statistics, case studies, and countermeasures being developed to foil drug counterfeiters including both high and low tech approaches. This report provides a unique examination and analysis of major global pharmaceutical markets, delivers a realistic description of counterfeiter capabilities, and covers new and emerging anti-counterfeiting technologies.
The pharma industry loses about $20 billion annually to counterfeiters.
Artesunate, a major weapon against malaria, is widely counterfeited. Researchers have found that up to 33 percent of the artesunate sold in Thailand, Cambodia and Vietnam contained no active ingredients. Of 30 medicines named in a list of drugs especially susceptible to counterfeiting, 23 are used in treating HIV/AIDS and cancer.
Counterfeiting of prescription drugs is a fast-growing menace to public health, to the efficacy of medical treatments, to the reputation and profits of pharma companies, and to government law-enforcement agencies. It is a new, fertile field for organised crime on a significant scale.
D&MD's Prescription Drug Counterfeiting report is an up-to-date analysis of the Rx counterfeiting situation which benefits from several information sources including the Third Global Anti-Counterfeiting Forum, held immediately prior to completion of the report. Report content includes statistics and case studies, and describes the array of countermeasures being developed to foil drug counterfeiters, including both high and low tech approaches.
The report describes the strategies used by counterfeiters; how and where they produce their drug products, how they infiltrate the supply chain, which countries are major sources of counterfeit drugs and the international anti-counterfeiting strategies now being put in place.
This report provides a unique examination and analysis of major global pharma markets and gives a realistic description of the capabilities of the counterfeiters, and in describing new and emerging anti-counterfeiting technologies.
Companies stand to lose significant business as a result of counterfeiting, both in terms of reduced sales and in erosion of trust among the medical profession, pharmacists and the public.
The main opportunities, for pharma companies, include:
-Recognising the scale and extent of the problem
-Quantifying its impact on their own business
-Obtaining a broad perspective on the range of anti-counterfeiting strategies available
-Appraising the relevance of available technologies to their own situation
About the Author:
Paul Evers is a market research consultant and writer, specializing in the pharmaceutical and other healthcare industries. He has researched and written detailed studies on a wide range of pharmaceutical and medical market sectors including metabolic, infectious, respiratory and malignant diseases, drug delivery, generics, pharmaceutical regulation, product lifecycles, and prospects for pharmaceutical R&D. He studied medical sciences at the National University of Ireland and holds an honours degree in biological sciences and humanities from The Open University.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Anti-Counterfeiting Strategies - Combating Fake Pharmaceuticals
Pharmaceutical Counterfeiting in the EU: Where Are We Now?
Pharmaceutical Anti-Counterfeiting Strategies
The Global Report on Counterfeiting: Anti-counterfeiting and the Apparel Industry
Apparel Counterfeiting in China - Management Briefing
Strategic Analysis of the North American Automotive Parts Counterfeiting and Gray Market
Global losses in pounds sterling due to counterfeiting and forgery, counterfeit retail goods, pirated software, pirated compact disks and cassettes, and from unlicensed medicines for 2000
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
Innovative Drug R&D in China
China Anti-Cancer Drug Market Report 2008
Anti-Obesity Drugs - Global Strategic Business Report
Anti-Obesity Drugs - Trends & Opportunities Worldwide
|
|
|
|
